MX2021016090A - Lemborexant para el tratamiento de problemas del sueño. - Google Patents
Lemborexant para el tratamiento de problemas del sueño.Info
- Publication number
- MX2021016090A MX2021016090A MX2021016090A MX2021016090A MX2021016090A MX 2021016090 A MX2021016090 A MX 2021016090A MX 2021016090 A MX2021016090 A MX 2021016090A MX 2021016090 A MX2021016090 A MX 2021016090A MX 2021016090 A MX2021016090 A MX 2021016090A
- Authority
- MX
- Mexico
- Prior art keywords
- lemborexant
- subjective
- subject
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Abstract
En el presente documento se describen métodos para mejorar la eficiencia subjetiva del sueño, reducir la latencia de inicio del sueño subjetiva y/o reducir la vigilia subjetiva después del inicio del sueño en sujetos que comprende administrar al sujeto 5 mg o 10 mg de lemborexant o una dosis equivalente de una sal farmacéuticamente aceptable del mismo. Además, en el presente documento se describe lemborexant, o una sal farmacéuticamente aceptable del mismo, para su uso en la mejora de la eficiencia subjetiva del sueño, la reducción de la latencia de inicio del sueño subjetiva y/o la reducción de la vigilia subjetiva después del inicio del sueño en un sujeto que comprende administrar al sujeto 5 mg o 10 mg de lemborexant o una dosis equivalente de una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/039333 WO2020263253A1 (en) | 2019-06-26 | 2019-06-26 | Lemborexant for treating sleep issues |
| PCT/US2019/067955 WO2020263331A1 (en) | 2019-06-26 | 2019-12-20 | Lemborexant for treating sleep issues |
| PCT/US2020/039674 WO2020264201A1 (en) | 2019-06-26 | 2020-06-25 | Lemborexant for treating sleep issues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021016090A true MX2021016090A (es) | 2022-02-03 |
Family
ID=74061314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021016090A MX2021016090A (es) | 2019-06-26 | 2020-06-25 | Lemborexant para el tratamiento de problemas del sueño. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220305012A1 (es) |
| KR (1) | KR20220027981A (es) |
| CN (1) | CN114096251A (es) |
| AU (1) | AU2020307991A1 (es) |
| BR (1) | BR112021026291A2 (es) |
| CA (1) | CA3144067A1 (es) |
| IL (1) | IL288949A (es) |
| MX (1) | MX2021016090A (es) |
| WO (1) | WO2020264201A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008251370A1 (en) * | 2007-05-10 | 2008-11-20 | Novadel Pharma Inc. | Anti-insomnia compositions and methods |
| PT2626350E (pt) * | 2010-09-22 | 2015-08-03 | Eisai R&D Man Co Ltd | Composto de ciclopropano |
| CN107810006B (zh) * | 2014-10-23 | 2021-03-30 | 卫材R&D管理有限公司 | 用于治疗失眠的组合物 |
| EP4056180A1 (en) * | 2016-05-12 | 2022-09-14 | Eisai R&D Management Co., Ltd. | Methods of treating circadian rhythm sleep disorders |
-
2020
- 2020-06-25 US US17/597,074 patent/US20220305012A1/en active Pending
- 2020-06-25 WO PCT/US2020/039674 patent/WO2020264201A1/en unknown
- 2020-06-25 CN CN202080046126.6A patent/CN114096251A/zh active Pending
- 2020-06-25 MX MX2021016090A patent/MX2021016090A/es unknown
- 2020-06-25 BR BR112021026291A patent/BR112021026291A2/pt unknown
- 2020-06-25 CA CA3144067A patent/CA3144067A1/en active Pending
- 2020-06-25 KR KR1020227002253A patent/KR20220027981A/ko unknown
- 2020-06-25 AU AU2020307991A patent/AU2020307991A1/en active Pending
-
2021
- 2021-12-13 IL IL288949A patent/IL288949A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020264201A1 (en) | 2020-12-30 |
| US20220305012A1 (en) | 2022-09-29 |
| IL288949A (en) | 2022-02-01 |
| CN114096251A (zh) | 2022-02-25 |
| BR112021026291A2 (pt) | 2022-03-03 |
| AU2020307991A1 (en) | 2022-02-10 |
| KR20220027981A (ko) | 2022-03-08 |
| CA3144067A1 (en) | 2020-12-30 |
| WO2020264201A8 (en) | 2021-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ597378A (en) | Treatment of multiple sclerosis with laquinimod | |
| PH12020551597A1 (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| MX2022004137A (es) | Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| WO2020092618A9 (en) | Methods of treating depression, anxiety and sexual dysfunction using the compound pimavanserin | |
| MX344476B (es) | Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal. | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| WO2007149283A3 (en) | Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| MX2020002889A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y métodos de uso del mismo. | |
| MX2021002322A (es) | Nuevos metodos. | |
| PH12021551235A1 (en) | Elacestrant in combination with abemaciclib in women with breast cancer | |
| BRPI0417123A (pt) | formulação de torsemide de liberação prolongada | |
| MX2021008986A (es) | Metodos de tratamiento de un paciente con enfermedad de parkinson. | |
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
| MX2021016090A (es) | Lemborexant para el tratamiento de problemas del sueño. | |
| DE602004030048D1 (de) | Ffizienz | |
| RU2014150946A (ru) | Способ снижения веса | |
| WO2021038500A3 (en) | Esketamine for the treatment of patients with major depressive disorder, including suicidality | |
| PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| MX2022004785A (es) | Metodos y composiciones para el tratamiento del sindrome de rett. | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| MX2021009488A (es) | Uso de vibegron para tratar la vejiga hiperactiva. | |
| RU2015119376A (ru) | Снижение вариабельности концентраций леводопы в плазме крови у разных пациентов |